Journal article

Update on New Aspects of the Renin-Angiotensin System in Hepatic Fibrosis and Portal Hypertension: Implications for Novel Therapeutic Options

Indu G Rajapaksha, Lakmie S Gunarathne, Peter W Angus, Chandana B Herath

JOURNAL OF CLINICAL MEDICINE | MDPI | Published : 2021

Abstract

There is considerable experimental evidence that the renin angiotensin system (RAS) plays a central role in both hepatic fibrogenesis and portal hypertension. Angiotensin converting enzyme (ACE), a key enzyme of the classical RAS, converts angiotensin I (Ang I) to angiotensin II (Ang II), which acts via the Ang II type 1 receptor (AT1R) to stimulate hepatic fibrosis and increase intrahepatic vascular tone and portal pressure. Inhibitors of the classical RAS, drugs which are widely used in clinical practice in patients with hypertension, have been shown to inhibit liver fibrosis in animal models but their efficacy in human liver disease is yet to be tested in adequately powered clinical trial..

View full abstract

Grants

Awarded by National Health and Research Council (NHMRC) of Australia


Funding Acknowledgements

This research was funded by National Health and Research Council (NHMRC) of Australia, grant APP1124125.